JP2012092123A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012092123A5 JP2012092123A5 JP2011272494A JP2011272494A JP2012092123A5 JP 2012092123 A5 JP2012092123 A5 JP 2012092123A5 JP 2011272494 A JP2011272494 A JP 2011272494A JP 2011272494 A JP2011272494 A JP 2011272494A JP 2012092123 A5 JP2012092123 A5 JP 2012092123A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- use according
- administered
- composition
- brimonidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Claims (5)
- 全身投与することによる、偏頭痛に付随する知覚過敏症の重症性を軽減しまたは予防するために使用される、ブリモニジン又はその薬学的に許容される塩、互変異性体、溶媒和物、アミド、又はN−オキシドを含んでなる薬学的組成物。
- 経口的に投与される、請求項1の使用のための薬学的組成物。
- 局所的に投与される、請求項1の使用のための薬学的組成物。
- パッチ剤を用いて投与される、請求項1の使用のための薬学的組成物。
- 静脈内に投与される、請求項1の使用のための薬学的組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/607,439 US20040266776A1 (en) | 2003-06-25 | 2003-06-25 | Methods of preventing and reducing the severity of stress-associated conditions |
US10/607,439 | 2003-06-25 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006517594A Division JP2007524625A (ja) | 2003-06-25 | 2004-06-22 | ストレス関連症状の重症性を軽減し予防する方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012092123A JP2012092123A (ja) | 2012-05-17 |
JP2012092123A5 true JP2012092123A5 (ja) | 2012-12-27 |
Family
ID=33540268
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006517594A Pending JP2007524625A (ja) | 2003-06-25 | 2004-06-22 | ストレス関連症状の重症性を軽減し予防する方法 |
JP2011272494A Pending JP2012092123A (ja) | 2003-06-25 | 2011-12-13 | ストレス関連症状の重症性を軽減し予防する方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006517594A Pending JP2007524625A (ja) | 2003-06-25 | 2004-06-22 | ストレス関連症状の重症性を軽減し予防する方法 |
Country Status (15)
Country | Link |
---|---|
US (6) | US20040266776A1 (ja) |
EP (1) | EP1638569B1 (ja) |
JP (2) | JP2007524625A (ja) |
KR (1) | KR20060023575A (ja) |
CN (2) | CN1812791A (ja) |
AT (1) | ATE539751T1 (ja) |
AU (2) | AU2004253500A1 (ja) |
BR (1) | BRPI0411826A (ja) |
CA (1) | CA2530487C (ja) |
DK (1) | DK1638569T3 (ja) |
ES (1) | ES2376878T3 (ja) |
HK (1) | HK1090282A1 (ja) |
MX (1) | MXPA05013900A (ja) |
TW (1) | TWI371276B (ja) |
WO (1) | WO2005002580A1 (ja) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5869079A (en) * | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
US6726918B1 (en) | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
ES2250504T3 (es) | 2000-11-29 | 2006-04-16 | Allergan Inc. | Prevencion del rechazo de injerto en el ojo. |
US20050048099A1 (en) | 2003-01-09 | 2005-03-03 | Allergan, Inc. | Ocular implant made by a double extrusion process |
US7439241B2 (en) | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
US8410102B2 (en) | 2003-05-27 | 2013-04-02 | Galderma Laboratories Inc. | Methods and compositions for treating or preventing erythema |
US20050020600A1 (en) * | 2003-07-23 | 2005-01-27 | Scherer Warren J. | Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists |
US20050059744A1 (en) * | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
US7812049B2 (en) * | 2004-01-22 | 2010-10-12 | Vicept Therapeutics, Inc. | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
US20100266638A1 (en) * | 2004-02-26 | 2010-10-21 | Allergan, Inc. | Headache treatment method |
US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
US20050244463A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
ES2647618T3 (es) * | 2004-05-25 | 2017-12-22 | Galderma Pharma S.A. | Compuestos, formulaciones y procedimientos para tratar o prevenir trastornos inflamatorios de la piel |
US8802128B2 (en) | 2006-06-23 | 2014-08-12 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
US20080293728A1 (en) * | 2007-05-18 | 2008-11-27 | Mcintire Gregory L | Complexes Comprising alpha2-Adrenergic Receptor Agonists and Compositions |
PT2182960E (pt) * | 2007-07-27 | 2014-06-11 | Galderma Lab Inc | Compostos, formulações e métodos para a redução das rugas, da flacidez e dos sulcos na pele |
US20090061020A1 (en) * | 2007-08-31 | 2009-03-05 | Theobald Klaus P | Brimonidine Compositions for Treating Erythema |
WO2009052071A1 (en) * | 2007-10-18 | 2009-04-23 | Allergan, Inc. | Treatment of sensorimotor disorders with 4- ( 1- ( 2, 3 -dimethylphenyl) ethyl) -1h-imidaz0le-2 ( 3h) -thione |
WO2009052073A2 (en) | 2007-10-18 | 2009-04-23 | Allergan, Inc. | Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists |
US8470337B2 (en) * | 2008-03-13 | 2013-06-25 | Allergan, Inc. | Therapeutic treatments using botulinum neurotoxin |
US8952011B2 (en) | 2008-08-01 | 2015-02-10 | Eye Therapies Llc | Compositions and methods for the treatment of nasal conditions |
US20100203165A1 (en) * | 2008-08-01 | 2010-08-12 | Gerald Horn | Compositions and methods for treatment of disorders or conditions of the eye |
EP2320911B1 (en) | 2008-08-01 | 2014-10-08 | Eye Therapies LLC | Vasoconstriction compositions and methods of use |
US8987270B2 (en) | 2009-07-27 | 2015-03-24 | Eye Therapies Llc | Formulations of selective alpha-2 agonists and methods of use thereof |
EP2470181A1 (en) * | 2009-08-26 | 2012-07-04 | Allergan, Inc. | Method of treating compulsive disorders with alpha-2b adrenergic receptor agonists |
MX361709B (es) | 2009-11-09 | 2018-12-07 | Allergan Inc | Composiciones y metodos para estimular el crecimiento del cabello. |
EP2329849B1 (en) | 2009-11-18 | 2015-04-29 | Galderma Research & Development | Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder |
US8394800B2 (en) * | 2009-11-19 | 2013-03-12 | Galderma Laboratories, L.P. | Method for treating psoriasis |
CA2782872A1 (en) * | 2009-12-17 | 2011-06-23 | Alpha Synergy Development, Inc. | Compositions and methods for ophthalmic delivery of nasal decongestants |
CN106038476B (zh) | 2010-03-26 | 2020-04-17 | 盖尔德马研究及发展公司 | 安全和有效治疗红斑的改进的方法和组合物 |
JP5747392B2 (ja) | 2010-03-26 | 2015-07-15 | ガルデルマ・リサーチ・アンド・デヴェロップメント | 毛細血管拡張症の安全かつ有効な治療のための改善された方法および組成物 |
US20120073515A1 (en) * | 2010-09-28 | 2012-03-29 | Advanced Bionics Corporation | Intrathecal needle guide apparatus |
US8053427B1 (en) | 2010-10-21 | 2011-11-08 | Galderma R&D SNC | Brimonidine gel composition |
AR083651A1 (es) | 2010-10-21 | 2013-03-13 | Galderma Sa | Composiciones de brimonidina en gel y metodos de uso |
US8445526B2 (en) | 2011-02-03 | 2013-05-21 | Glaucoma & Nasal Therapies Llc | Compositions and methods for treatment of glaucoma |
BR112014000634A2 (pt) | 2011-07-14 | 2017-02-14 | Allergan Inc | métodos para tratamento de incontinência associada com atividade sexual |
WO2014127243A1 (en) | 2013-02-15 | 2014-08-21 | Allergan, Inc. | Sustained drug delivery implant |
US8999938B2 (en) | 2013-06-21 | 2015-04-07 | Gnt Llc | Ophthalmic lipophilic drug delivery vehicle formulations |
CA3006962A1 (en) | 2014-12-01 | 2016-06-09 | Achelios Therapeutics Inc. | Methods and compositions for treating migraine and conditions associated with pain |
CA3110248A1 (en) * | 2018-08-29 | 2020-03-05 | Cellix Bio Private Limited | Ophthalmic compositions and methods for the treatment of eye disorders and skin diseases |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5380754A (en) * | 1988-02-29 | 1995-01-10 | Virotex Corporation | Topical composition enhancing healing of viral lesions |
US6323204B1 (en) * | 1993-10-13 | 2001-11-27 | Allergan | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
EP0723447B1 (en) * | 1993-10-13 | 2002-12-11 | Allergan, Inc. | Use of (2-imidazolin-2-ylamino) quinoxaline derivatives |
US6462077B1 (en) * | 1993-12-28 | 2002-10-08 | Allergan, Inc. | Thromboxane ligands without blood clotting side effects |
GB9425211D0 (en) * | 1994-12-14 | 1995-02-15 | Ucb Sa | Substituted 1H-imidazoles |
WO1996025163A1 (en) | 1995-02-14 | 1996-08-22 | Board Of Supervisors Or Louisiana State Universityof Agricultural And Mechanical College Through Itsmedical Center | Treatment of herpes simplex viruses |
US6194415B1 (en) * | 1995-06-28 | 2001-02-27 | Allergan Sales, Inc. | Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury |
US6576636B2 (en) | 1996-05-22 | 2003-06-10 | Protarga, Inc. | Method of treating a liver disorder with fatty acid-antiviral agent conjugates |
US5795909A (en) | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
US20030059471A1 (en) | 1997-12-15 | 2003-03-27 | Compton Bruce Jon | Oral delivery formulation |
WO1999030690A1 (en) | 1997-12-15 | 1999-06-24 | Axia Therapeutics, Inc. | Oral delivery formulation |
DK1124535T3 (da) | 1998-10-27 | 2003-01-06 | Alcon Lab Inc | Konserverende system til topisk indgivelige farmaceutiske præparater indeholdende en fedtsyre/aminosyresæbe |
AU768393B2 (en) * | 1999-05-28 | 2003-12-11 | Jeffrey Berlant | Compounds and methods for the treatment of post traumatic stress disorder |
AU5331200A (en) | 1999-06-11 | 2001-01-02 | Ohio State University Research Foundation, The | Methods and compositions for treating raynaud's phenomenon and scleroderma |
KR100331529B1 (ko) | 1999-06-16 | 2002-04-06 | 민경윤 | 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법 |
US7160890B2 (en) | 1999-12-02 | 2007-01-09 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
IN188750B (ja) | 1999-12-04 | 2002-11-02 | Khamar Bakulesh Dr Mafatlal | |
US6294553B1 (en) * | 2000-02-15 | 2001-09-25 | Allergan Sales, Inc. | Method for treating ocular pain |
US6444681B1 (en) | 2000-06-09 | 2002-09-03 | The Ohio State University Research Foundation | Methods and compositions for treating Raynaud's Phenomenon and scleroderma |
NZ521185A (en) * | 2000-07-14 | 2005-02-25 | Allergan Inc | Compositions containing alpha-2-adrenergic agonist components |
US6673802B2 (en) | 2000-12-01 | 2004-01-06 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
AU2002360436A1 (en) | 2001-11-30 | 2003-06-17 | Osi Pharmaceuticals, Inc. | 2-aryl pyrrologpyrimidines for a1 and a3 receptors |
IL147921A0 (en) * | 2002-01-31 | 2002-08-14 | Abdulrazik Mohammad | A method for treating central nervous system disorders by ocular dosing |
US7345065B2 (en) * | 2002-05-21 | 2008-03-18 | Allergan, Inc. | Methods and compositions for alleviating pain |
US7439241B2 (en) | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
US20050020600A1 (en) | 2003-07-23 | 2005-01-27 | Scherer Warren J. | Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists |
ES2647618T3 (es) | 2004-05-25 | 2017-12-22 | Galderma Pharma S.A. | Compuestos, formulaciones y procedimientos para tratar o prevenir trastornos inflamatorios de la piel |
-
2003
- 2003-06-25 US US10/607,439 patent/US20040266776A1/en not_active Abandoned
-
2004
- 2004-06-22 EP EP04755981A patent/EP1638569B1/en active Active
- 2004-06-22 CN CNA2004800178422A patent/CN1812791A/zh active Pending
- 2004-06-22 JP JP2006517594A patent/JP2007524625A/ja active Pending
- 2004-06-22 AU AU2004253500A patent/AU2004253500A1/en not_active Abandoned
- 2004-06-22 CA CA2530487A patent/CA2530487C/en not_active Expired - Fee Related
- 2004-06-22 ES ES04755981T patent/ES2376878T3/es active Active
- 2004-06-22 BR BRPI0411826-0A patent/BRPI0411826A/pt not_active IP Right Cessation
- 2004-06-22 KR KR1020057024881A patent/KR20060023575A/ko not_active Application Discontinuation
- 2004-06-22 MX MXPA05013900A patent/MXPA05013900A/es active IP Right Grant
- 2004-06-22 DK DK04755981.0T patent/DK1638569T3/da active
- 2004-06-22 AT AT04755981T patent/ATE539751T1/de active
- 2004-06-22 WO PCT/US2004/020194 patent/WO2005002580A1/en active Application Filing
- 2004-06-22 CN CN2011104449533A patent/CN102579448A/zh active Pending
- 2004-06-25 TW TW093118660A patent/TWI371276B/zh not_active IP Right Cessation
-
2006
- 2006-09-28 HK HK06110807.6A patent/HK1090282A1/xx not_active IP Right Cessation
-
2008
- 2008-05-02 US US12/114,719 patent/US20080207627A1/en not_active Abandoned
- 2008-05-02 US US12/114,727 patent/US7977335B2/en not_active Expired - Lifetime
-
2010
- 2010-11-18 AU AU2010241513A patent/AU2010241513B9/en not_active Ceased
-
2011
- 2011-12-13 JP JP2011272494A patent/JP2012092123A/ja active Pending
-
2012
- 2012-06-01 US US13/486,847 patent/US20120302574A1/en not_active Abandoned
- 2012-10-15 US US13/652,179 patent/US20130102612A1/en not_active Abandoned
-
2013
- 2013-02-15 US US13/768,901 patent/US20130217694A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2012092123A5 (ja) | ||
JP2019516735A5 (ja) | ||
HRP20180591T1 (hr) | Inhibitori kinaze serina ili treonina | |
PH12015502628B1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
JP2014515013A5 (ja) | ||
MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
JP2017537066A5 (ja) | ||
JP2013014622A5 (ja) | ||
EA201690287A1 (ru) | 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом | |
PH12014502363A1 (en) | N-aryltriazole compounds as lpar antagonists | |
PH12014502789A1 (en) | N-alkyltriazole compounds as lpar antagonists | |
EA201592255A1 (ru) | Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания | |
JP2013507408A5 (ja) | ||
WO2012099942A3 (en) | Methods and compositions for treating metabolic syndrome | |
ECSP13012812A (es) | Formulaciones inmunosupresoras | |
MA37455A1 (fr) | Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique | |
JP2009537554A5 (ja) | ||
WO2015116856A3 (en) | Farnesoid x receptor antagonists | |
JP2015510916A5 (ja) | ||
PH12014502364A1 (en) | Substituted pyrazole compounds as lpar antagonists | |
EA201300990A1 (ru) | Парентеральное введение тапентадола | |
WO2015000431A9 (zh) | 替唑尼特氨基甲酸酯及其在药学中的应用 | |
JP2017518982A5 (ja) | ||
MX2018008799A (es) | Derivado de azaciclo amida, metodo de preparacion del mismo y aplicacion farmaceutica. | |
JO3192B1 (ar) | مركب بنزوثيازولون |